The Hematology/Oncology Pharmacy Association has helped establish practical guidance for Investigational Services metrics and site utilization.

The metrics subgroup of the HOPA Investigational drug services (IDS) special interest group recently conducted a survey-based project to help establish practical guidance for IDS metrics and site utlity. Three surveys were sent to HOPA IDS professionals to document how metrics were currently gathered at various sites, categorize and define additional approaches, and create a list of recommended metrics for every IDS site to track. The recommended metrics can serve as a basis for standardization and benchmarking for sites mired in the complexity of research protocols.

The results have been published in the American Journal of Health-Systems Pharmacy.


Authors: Molly Schmidt, PharmD, BCPS, BCOP, CSP; Lisa Janssen Carlson, PharmD, BCOP; Jennifer Murphy, PharmD, BCOP, Sapna R Amin, PharmD, BCOP; Robin Lockhorst, PharmD, BCOP, BCPS; and Kyle Luedtke, PharmD

Read the abstract

Lung cancer x-ray image
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Ensartinib

Savannah Young, PharmD, PGY1 Pharmacy Resident, from Sarasota Memorial Hospital, Sarasota, FL, and Kiera Roubal, PharmD, BCOP, Clinical Oncology Pharmacist Specialist, from Medical University of South Carolina, Charleston, SC, write about ensartinib.

Cancer cell image
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Datopotamab deruxtecan-dlnk

Kasey Jackson, PharmD, BCOP, Clinical Oncology Pharmacy Specialist at Medical University of South Carolina, Charleston, SC, writes about datopotamab deruxtecan-dlnk (Datroway).

acute leukemia image
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Revumenib

Andres Mariano, PharmD, PGY-2 Pediatric Oncology Pharmacy Resident, and Stephen Eng, PharmD, BCOP, Clinical Pharmacist - both from Memorial Sloan Kettering Cancer Center, New York, NY - write about revumenib (Revuforj).